That's a really astute observation about the poor bioavailability.
I think SemBioSys current strategy is biogenerics, link up with one of the big generic players, i.e. teva, go after not just US but EU and emerging markets as the low cost producer.
CAGR implied here seems way too high to me.
<<The world market for insulin is estimated to be in excess of US$7.1 billion today and the demand for insulin is projected to increase due to two factors: demographic and dietary choices in the western world are causing an increase in the incidence of diabetes; and at the same time, countries in the rest of the world that are currently underserved in the insulin market, are demanding greater access to insulin at an affordable price. By 2012, independent estimates predict a US$15 billion insulin market.>>
Market Data 
Markets 
AI
